^
HIF1A overexpression
|
CRC
|
HIF1A overexpression
|
CRC
|
5-fluorouracil Resistant: D – Preclinical
J Exp Clin Cancer Res - 1 week
|
5-fluorouracil Resistant: D – Preclinical
J Exp Clin Cancer Res - 1 week
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
Clin Colorectal Cancer - 2 weeks
|
nivolumab + ipilimumab Sensitive: A1 - Approval
Clin Colorectal Cancer - 2 weeks
|
NRAS mutation
|
CRC
|
NRAS mutation
|
CRC
|
cetuximab Resistant: A2 - Guideline
Br J Cancer - 2 weeks
|
cetuximab Resistant: A2 - Guideline
Br J Cancer - 2 weeks
|
KRAS mutation
|
CRC
|
KRAS mutation
|
CRC
|
cetuximab Resistant: B - Late Trials
Br J Cancer - 2 weeks
|
cetuximab Resistant: B - Late Trials
Br J Cancer - 2 weeks
|
NRAS mutation
|
CRC
|
NRAS mutation
|
CRC
|
bevacizumab Sensitive: C2 – Inclusion Criteria
Br J Cancer - 2 weeks
|
bevacizumab Sensitive: C2 – Inclusion Criteria
Br J Cancer - 2 weeks
|
KRAS mutation
|
CRC
|
KRAS mutation
|
CRC
|
bevacizumab Sensitive: C2 – Inclusion Criteria
Br J Cancer - 2 weeks
|
bevacizumab Sensitive: C2 – Inclusion Criteria
Br J Cancer - 2 weeks
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
cetuximab Resistant: C3 – Early Trials
Br J Cancer - 2 weeks
|
cetuximab Resistant: C3 – Early Trials
Br J Cancer - 2 weeks
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
bevacizumab Resistant: C3 – Early Trials
Br J Cancer - 2 weeks
|
bevacizumab Resistant: C3 – Early Trials
Br J Cancer - 2 weeks
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval
|
cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + encorafenib Sensitive: A1 - Approval
|
cetuximab + encorafenib Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFIRI Sensitive: A1 - Approval
|
FOLFIRI Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
5-fluorouracil + irinotecan Sensitive: A1 - Approval
|
5-fluorouracil + irinotecan Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
Zirabev (bevacizumab biosimilar) Resistant: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
ziv-aflibercept IV Sensitive: A1 - Approval
|
ziv-aflibercept IV Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
EGFR expression
|
CRC
|
EGFR expression
|
CRC
|
cetuximab Sensitive: A1 - Approval
|
cetuximab Sensitive: A1 - Approval
|
KRAS Q61
|
CRC
|
KRAS Q61
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
irinotecan Sensitive: A1 - Approval
|
irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
irinotecan Sensitive: A1 - Approval
|
irinotecan Sensitive: A1 - Approval
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS G12
|
CRC
|
KRAS G12
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
KRAS K117
|
CRC
|
KRAS K117
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS A59
|
CRC
|
KRAS A59
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS G12S
|
CRC
|
KRAS G12S
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS Q61
|
CRC
|
NRAS Q61
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS Q61
|
CRC
|
NRAS Q61
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS G13
|
CRC
|
NRAS G13
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS G13
|
CRC
|
NRAS G13
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS G12
|
CRC
|
NRAS G12
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS G12
|
CRC
|
NRAS G12
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS A146
|
CRC
|
NRAS A146
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS A146
|
CRC
|
NRAS A146
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS G61
|
CRC
|
KRAS G61
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS H117
|
CRC
|
NRAS H117
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS H117
|
CRC
|
NRAS H117
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS A59
|
CRC
|
NRAS A59
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS A59
|
CRC
|
NRAS A59
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS K117
|
CRC
|
KRAS K117
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS A59
|
CRC
|
KRAS A59
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS exon 4 mutation
|
CRC
|
NRAS exon 4 mutation
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS exon 3 mutation
|
CRC
|
NRAS exon 3 mutation
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS exon 2 mutation
|
CRC
|
NRAS exon 2 mutation
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS mutation
|
CRC
|
NRAS mutation
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS exon 4 mutation
|
CRC
|
NRAS exon 4 mutation
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
panitumumab Sensitive: A1 - Approval
|
panitumumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Colon Cancer
|
MSI-H/dMMR
|
Colon Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Colon Cancer
|
MSI-H/dMMR
|
Colon Cancer
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
panitumumab Resistant: A2 - Guideline
|
panitumumab Resistant: A2 - Guideline
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
cetuximab Resistant: A2 - Guideline
|
cetuximab Resistant: A2 - Guideline
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
panitumumab Sensitive: A2 - Guideline
|
panitumumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
NTRK1 fusion
|
CRC
|
NTRK1 fusion
|
CRC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
CRC
|
NTRK3 fusion
|
CRC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
CRC
|
NTRK2 fusion
|
CRC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
CRC
|
NTRK3 fusion
|
CRC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
CRC
|
NTRK2 fusion
|
CRC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
CRC
|
NTRK1 fusion
|
CRC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
panitumumab + encorafenib Sensitive: A2 - Guideline
|
panitumumab + encorafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline
|
trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
NRAS exon 2 mutation
|
CRC
|
NRAS exon 2 mutation
|
CRC
|
cetuximab Resistant: A2 - Guideline
|
cetuximab Resistant: A2 - Guideline
|
NRAS exon 3 mutation
|
CRC
|
NRAS exon 3 mutation
|
CRC
|
cetuximab Resistant: A2 - Guideline
|
cetuximab Resistant: A2 - Guideline
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline
|
cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
bevacizumab + trifluridine/tipiracil Sensitive: A2 - Guideline
|
bevacizumab + trifluridine/tipiracil Sensitive: A2 - Guideline
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
FOLFOXIRI Sensitive: A2 - Guideline
|
FOLFOXIRI Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFOXIRI Sensitive: A2 - Guideline
|
FOLFOXIRI Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
